Reports also demonstrated that BRCA2 mutated tumours are more sensitive to chemotherapies (mainly platinum‐based treatment) rather than BRCA1 mutated tumours.11More work in the field of mechanism of BRCA gene mutation altering sensitivity to chemotherapy and immunotherapy should be taken out to guide treatment combination or to specify the rules of patient's selection with more details. This evidence concerns the gene BRCA1 and neoplasm.